Recro Pharma, Inc. (REPH) Receives $13.50 Average Target Price from Brokerages
Shares of Recro Pharma, Inc. (NASDAQ:REPH) have been given an average recommendation of “Buy” by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $13.50.
Several equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a research report on Friday, October 27th. Finally, Roth Capital set a $20.00 price target on Recro Pharma and gave the company a “buy” rating in a research report on Monday, July 31st.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its position in Recro Pharma by 3.0% during the 1st quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock valued at $150,000 after purchasing an additional 500 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Recro Pharma during the 1st quarter valued at approximately $156,000. KCG Holdings Inc. bought a new position in Recro Pharma during the 1st quarter valued at approximately $173,000. Rothschild Investment Corp IL bought a new position in Recro Pharma during the 2nd quarter valued at approximately $141,000. Finally, JPMorgan Chase & Co. raised its position in Recro Pharma by 183.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after purchasing an additional 14,098 shares during the last quarter. 65.25% of the stock is owned by institutional investors and hedge funds.
Shares of Recro Pharma (REPH) traded up $0.01 during mid-day trading on Friday, reaching $8.75. The company had a trading volume of 42,654 shares, compared to its average volume of 93,975. Recro Pharma has a 52 week low of $5.81 and a 52 week high of $10.17. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.81 and a quick ratio of 5.23.
Recro Pharma (NASDAQ:REPH) last issued its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.06. The company had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.90 million. Recro Pharma had a negative return on equity of 56.04% and a negative net margin of 46.75%. equities research analysts expect that Recro Pharma will post -2.35 EPS for the current fiscal year.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.